Full text is available at the source.
Abstract
Tirzepatide is linked to improved metabolic and cardiovascular risk factors in patients with type 2 diabetes and obesity.
- The effects of tirzepatide on venous thromboembolism, such as pulmonary embolism and deep vein thrombosis, are not well understood in real-world settings.
- There is a need for further investigation into the safety profile of tirzepatide regarding thromboembolic events.
- Current knowledge on tirzepatide's benefits does not fully address its potential risks in diverse populations.
Simplified